Cargando…

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

Detalles Bibliográficos
Autores principales:	Rubbert-Roth, Andrea, Vuilleumier, Nicolas, Ludewig, Burkhard, Schmiedeberg, Kristin, Haller, Christoph, von Kempis, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186851/ https://www.ncbi.nlm.nih.gov/pubmed/34124693 http://dx.doi.org/10.1016/S2665-9913(21)00186-7

Ejemplares similares

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1?
por: Vuilleumier, Nicolas, et al.
Publicado: (2021)

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
por: Haller, Christoph, et al.
Publicado: (2021)

Pausing drugs and spacing vaccines: an open question – Authors' reply
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection
por: Perrot, Lea, et al.
Publicado: (2021)

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
por: Mueller, Ruediger B., et al.
Publicado: (2019)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Flare of rheumatoid arthritis after COVID-19 vaccination
por: Terracina, Katherine A, et al.
Publicado: (2021)

Neuron navigator 2 is a novel mediator of rheumatoid arthritis
por: Wang, Ran, et al.
Publicado: (2021)

Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
por: Mueller, Ruediger B., et al.
Publicado: (2016)

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
por: Rubbert-Roth, Andrea, et al.
Publicado: (2009)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis
por: Takatani, Ayuko, et al.
Publicado: (2023)

SARS-CoV-2 immunity and HIV infection: total recall?
por: Dauby, Nicolas, et al.
Publicado: (2021)

Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease
por: Kelly, Clive
Publicado: (2022)

Comment on “The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis”
por: Minamino, Hiroto, et al.
Publicado: (2022)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
por: Füessl, Louise, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

Omega 3 Fatty Acids Intake Does Not Decrease the Risk of Rheumatoid Arthritis Occurrence: A Meta-Analysis. Comment on Tański et al. The Relationship between Fatty Acids and the Development, Course and Treatment of Rheumatoid Arthritis. Nutrients 2022, 14, 1030
por: Mathieu, Sylvain, et al.
Publicado: (2023)

Comment on Sifakaki et al. Orthorexia Nervosa Practices in Rheumatoid Arthritis: The DORA Study. Nutrients 2023, 15, 713
por: Meule, Adrian
Publicado: (2023)

Comment on Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556
por: Schulte-Pelkum, Johannes
Publicado: (2021)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
por: Raptis, Catherine E., et al.
Publicado: (2022)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Asymptomatic SARS-CoV-2 infection
por: Ooi, Eng Eong, et al.
Publicado: (2020)

The complexities of SARS-CoV-2 serology
por: Houlihan, Catherine F, et al.
Publicado: (2020)

Neonatal SARS-CoV-2 infection
por: de Carvalho, Werther Brunow, et al.
Publicado: (2020)

Towards SARS-CoV-2 serotypes?
por: Simon-Loriere, Etienne, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis
por: Limoges, Marc-André, et al.
Publicado: (2023)

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2020)

Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
por: Riek, Myriam, et al.
Publicado: (2023)

Biologics and anti-Sars Cov2 vaccination in severe asthma riding the big wave: Unity is strength!
por: Guarnieri, G., et al.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

Understanding the drivers of transmission of SARS-CoV-2
por: Cornelissen, Laura, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

The SARS-CoV2 pandemic and routine immunisation
por: Kang, Gagandeep
Publicado: (2022)

Sustainability of surveillance systems for SARS-CoV-2
por: Adlhoch, Cornelia, et al.
Publicado: (2022)

Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kpve85b0ftl787602smksd9lh9